Publication: New drugs in multiple myeloma
Issued Date
2019-01-27
Resource Type
ISSN
1545326X
00664219
00664219
Other identifier(s)
2-s2.0-85060643542
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annual Review of Medicine. Vol.70, (2019), 521-547
Suggested Citation
Chutima Kunacheewa, Robert Z. Orlowski New drugs in multiple myeloma. Annual Review of Medicine. Vol.70, (2019), 521-547. doi:10.1146/annurev-med-112017-091045 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/50284
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
New drugs in multiple myeloma
Author(s)
Abstract
© 2019 by Annual Reviews. Multiple myeloma is diagnosed in over 100,000 patients each year worldwide, has an increasing incidence and prevalence in many regions, and follows a relapsing course, making it a significant and growing healthcare challenge. Recent basic, translational, and clinical studies have expanded our therapeutic armamentarium, which now consists of alkylating agents, corticosteroids, deacetylase inhibitors, immunomodulatory agents, monoclonal antibodies, and proteasome inhibitors. New drugs in these categories, and additional agents, including both small and large molecules, as well as cellular therapies, are under development that promise to further expand our capabilities and bring us closer to the cure of this plasma cell dyscrasia.